Oncology Corporate Profile
Portola Pharmaceuticals is focused on the development and commercialization of novel therapeutics to meet patient needs in thrombosis, other hematologic disorders and inflammation. Our current development-stage portfolio includes wholly-owned and partnered products. Portola's wholly-owned product candidate, cerdulatinib (PRT2070), is an orally available kinase inhibitor that uniquely inhibits two validated tumor proliferation pathways -- spleen tyrosine kinase (Syk) and janus kinase (JAK). It is currently being studied in patients with leukemias or lymphomas with a focus on genetically-defined subtypes, as well as in patients who have failed therapy due to relapse or acquired mutations.
|Bevyxxa®||betrixaban||Bevyxxa® is a factor Xa (FXa) inhibitor indicated for the prophylaxis of venous thromboembolim (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.|
|Brand / Product||Class||Area of Study||Phase||Partnership|
|cerdulatinib / PTR-2070||dual tyrosine kinase (Syk) and janus kinase (JAK) inhibitor.||Chronic Lymphocytic Leukemia (CLL)||II|
|cerdulatinib / PTR-2070||dual tyrosine kinase (Syk) and janus kinase (JAK) inhibitor.||Non-Hodgkin's Lymphoma (NHL)||I|
View additional information on product candidates here »